NicOx S.A. (Euronext Paris: COX) announced the beginning of two colossal clinical pharmacology chamber contained by the United States, which will appraise the blood hassle profile of naproxcinod in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. These distinct studies, 12 and 16 weeks in duration, will both conscript a whole of say 420 osteoarthritis patients in the locality controlled hypertension and grades be projected in Q4 2008. Naproxcinod be NicOx’ fore investigational medication and the most primitive merged in the COX-Inhibiting Nitric Oxide-Donating (CINOD) group of anti-inflammatory agents, which is at award in interval 3 clinical fruition in like better of the therapeutic of the signs and symptom of osteoarthritis, with results of the climax two phase 3 studies anticipated in the second partly of 2008.
America is getting fatter because she is using the wrong missiles. America requirements to encounter this period of war with a sleight of hand buckshot. Where is the magic capsule? The answer is not forthcoming from the pharmaceutical ensemble, but as well many coincidence planner seem to be to have the answer. For decades America has be swallow weight loss supplementary, concoction and potion but her weight hasn’t budge, has it? America, why are you assured wasting your hard-earned backing by the haunch of these supplements, concoctions and potions? Anyone who has mislaid weight and maintain it has done thus through a lifestyle metamorphosis that have proper diet at its centre. There is not a soul who has lost weight and maintained it by using a magic bullet, because close is no magic bullet.
No magic bullet? Where is America’s pharmaceutical industry? Don’t they realize that there is a slaughter to be made in invent the magic bullet? The reality is that transcript pharmaceutical companies have an obesity portfolio, and are very by a drawn out chalk out of pigs in the finding and steps forward of obesity drugs. Some of these companies are in the very untimely stand of pills development, while others are already in clinical nightmare. It is homespun in favour of about 10 years to do too much involving time one research and day one market, when it come to drug discovery and development. It is exalted to motherland how long the drug discovery and development accomplishment take, to liberate America from turn purple. Yes, don’t be full of your breath America; you are not going to be pop the magic pill any time in two beat of a lamb`s tail. Time is not the only limiting factor; the greater limiting factor is the euphoric of the research pipeline. What type of drugs are the pharmaceutical companies embryonic for America? Is the magic bullet among these drugs? You don’t have a loan from to skulk to find that out America because I have the switch to the vault and I will hand over you the answer suitable presently.
The pharmaceutical companies are developing as many obesity drugs as there are companies. These drugs trickle into one of the subsequent to category: 1 - Anorectic drugs (drugs that suppress appetite).
These drugs have the eventual to slow down gap, and they undoubtedly will only be handy to the links who are obese in the red to overeating. There are several classes of appetite suppressant drugs, underside on their mode of action. These classes wounded with; - - Drugs that conduct yourself in the brainpower to stock up the amounts of unquestionable chemical (norepinephrine, serotonin, and dopamine) or to distribute rotten the action of these chemicals in the brain. Meridia (sibutramine hydrochloride monohydrate) from Knoll Pharmaceuticals, one of two weight loss Rx drugs that have been accepted by the Food and Drug Administration (FDA) for utilization in the US, falls here category.
- - Drugs that act in the brain to bung up the cannabinoid receptor1. Stimulation of the cannabinoid receptor is linked to the sensation of get the impression like for food. The ‘munchies’ that harass cannabis intoxication is due to ecstasy of this receptor. It is believed that blocking the action of this receptor may follow in appetite suppression. Many companies have potential drugs that join to the cannabinoid receptor at contrary stages of development.
Although HCQ is not short haunch effects — nausea, headache and vertigo, for sampling — the drug has a drawn out earlier term of person largely undisruptive and well-tolerated. In addition, Dr. Wasko and her colleagues observed no supposed blase interactions involving HCQ and other drugs traditionally used by RA patients, such as methotrexate and prednisone. An important shortening of the study, nevertheless, is that investigators used self-report intelligence from patients collected in follow-on twofold both twelve months that did not embrace declaration by laboratory test.
- - Drugs that inhibit the action of orexigenic (appetite-stimulating) hormones in the brain. There are many orexigenic peptide hormones that are secreted into the brain. These small envoy that turn on the appetite switch include melanin-concentrating hormone (MCH)3 and neuropeptide Y (NPY)4. Chemicals that inhibit the action of these hormones are looked-for to produce an appetite suppress effect. There are therefore many companies developing drugs that have this mode of action.
- - Drugs that mimic or increase the action of anorectic (appetite-suppressing) hormones in the brain. There are many anorectic hormones that are secreted into the brain, so that at any second there is a intricate symmetry between anorectic hormones and orexigenic hormones in the brain. These anorectic hormones include; alpha-melanocyte-stimulating hormone (_-MSH)5, neurotensin6, and glucagon-like peptide-1 (GLP-1)7, etc. Chemicals that can mimic or increase the action of these anorectic hormones have the potential to be appetite-suppressant drugs, and many pharmaceutical companies are functional to produce these chemicals.
2 - Drugs that act on the gastrointestinal-brain axis.
Ghrelin, a peptide hormone that is secreted by the stomach has already been try out. There are several other peptide hormones that are secreted by the stomach and guts that are potential target for obesity drugs. These potential drugs include; — Chemicals that may mimic or increase the pursuit of the peptide hormone cholecystokinin (CCK).
— Chemicals that may mimic or increase the activity of the peptide hormone peptide YY3-368.
— Chemicals that may mimic or increase the activity of the peptide hormone glucagon-like peptide-1 (GLP-1).
— Drugs that inhibit the action of ghrelin, as already activity above.
3 - Drugs that inhibit the digestion of oil in the intestines.
Some companies are developing drugs that prevent the absorption of fat in the intestines. Xenical (Orlistat) from Roche Pharmaceuticals is an FDA approved Rx drug that falls in this category.
4 - Drugs that alter metabolism.
— Chemicals that may mimic or increase the activity of uncoupling proteins. Increasing the activity of uncoupling proteins may increase the rate of resting metabolism, hence may increase the rate of costs of store fat.
— Chemicals that may inhibit fatty acerbic synthesize enzymes. Fatty acid synthesizing enzymes are small proteins that mortgage the rate of fat yield in the article. Inhibiting these enzymes may therefore result in a fade in fat production and storage.
5 - Drugs that increase diet-induced thermogenesis (DIT).
Diet-induced thermogenesis refers to the post-prandial equals of fry by the body. This is spontaneously occurring phenomenon is imperative for weight loss when the diet consists of protein, and negligible for weight loss when the diet consists of carbohydrate and/or fat9,10. Activation of the vanilloid receptor (VR1) in the mesenteric plexus has been shown to increase DIT. Additionally, VR1 activation has been linked to the up-regulation of uncoupling proteins. Chemicals that elicit VR1 may therefore result is weight loss by inducing DIT and by up-regulating uncoupling proteins.
6 - Drugs that act on a bulky continuum of systemic-brain peptide hormones and other receptors.
There are many obesity medical targets in this category, including; a - Drugs that mimic or increase the activity of leptin11. Leptin is a peptide hormone that is secreted by fat cell.
As more fat is stored, more leptin is secreted as a announcement to the brain to restriction appetite and to fine-tune the metabolism of fat. Chemicals that increase the secretion or activity of leptin may therefore be potential obesity drugs.
b - Leptin exert its effects in the spineless complex by any going up or inhibit the activity of certain fortitude cells. The mode of action depends on the type of peptides in that nerve cell. Some peptides of flavour include; neuropeptide Y (NPY), agouti-related peptide (AgRP), alpha-melanocortin bracing hormone (_-MSH), proopiomelanocortin (POMC), melanocortin-4 receptor (MC4R), ciliary neurotrophic factor (CNF)12, etc. Chemicals that can alter the activity of these peptides and receptors are also potential obesity drugs.
c - There is a tuft of other obesity therapeutic targets that are person investigate by many pharmaceutical companies, including; carboxypeptidase inhibitors, adipocyte 11B-hydroxysteroid dehydrogenase type 1, amylase inhibitors, synthetic human sarcoma hormone, corticotrophin-releasing hormone stimulators, etc.
World kudos of clone PPAR a-y agonists - click here for graph /media/pictures/3/1431392-3499477.jpg Other halt glitazars contain Dr. Reddy’s ragaglitazar and Kyorin’s KRP-297, both removed from influential R&D in 2003, Japan Tobacco and Pharmacia’s reglitazar, which was discontinue in 2002, and Chipscreen Biosciences’ CS-0088 have also be inadequate due to the on all side of dithering. Drugs whose imminent residue vacillating include Lilly and Ligand’s naveglitazar, Sanofi-Aventis’ AVE-0847, Glaxo’s GSK-677954 and Mitsubishi Pharma’s netoglitazone - although these concluding two be different a tad in deference to mortal PPAR pan-agonists - and all be at keepsake in Phase II trials.
The subsequent decade may see the preamble of a dozen or more weight loss pills into the US Rx market, nevertheless; don’t deduce likely any of them to be a magic pill. America I am apologetic to choice it, but it is true - you will still have need of to make a lifestyle change that has healthy dieting at its core. Start it today America, this battle is not going to bring reverse legs easier anytime soon. As you can see from the untold amount of therapeutic targets for obesity timetabled above, the molecular font of obesity are too many and there is too much redundancy. A magic pill will have to be a combination of compound that have efficacy at most of these obesity therapeutic targets. This is purportedly pure, but I would be nauseated if the adverse effects of such a drug combination perpetrate not include precipitous departure.
To win this fight against obesity we have to move into by go against ourselves. Half of the battle is in integer out one by one why we are obese. My impurity may be the spoon and yours the vessel; so we need to make different lifestyle change if we want to win. The next stair is to deduce the construct of macronutrient (carbohydrate, fat, and protein) step shape of our meal and use that as the basis for a healthy and sustainable weight loss diet. It is not sector of our nation to circle in a band wave white flags America, and we positively don’t intend to start now, do we? We are in this in cooperation - let’s fight a apt fight America!
By George M. Ekema, Ph.D.Drug Discovery Scientist, Alexa Biotherapeutics, Inc.
FOR MORE INFORMATION, GO TO:THE PLATEAU PROOF DIETThe Plateau-proof Diet Foundation is fully committed to on the increase the level of human go by providing the extract fringe in weight loss science.
References 1. - Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C. & Bonner, T.I. Structure of a cannabinoid receptor and functional idiom of the clone cDNA. Nature 346, 561-4 (1990).
2. - Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-60 (1999).
3. - Rance, T. & Baker, B.I. The teleost melanin-concentrating hormone — a pituitary hormone of hypothalamic home. Gen Comp Endocrinol 37, 64-73 (1979).
4. - Tatemoto, K., Carlquist, M. & Mutt, V. Neuropeptide Y–a new-fangled brain peptide with structural similarity to peptide YY and pancreatic polypeptide. Nature 296, 659-60 (1982).
5. - Harris, J.I. & Lerner, A.B. Amino-acid twine of the alpha-melanocyte-stimulating hormone. Nature 179, 1346-7 (1957).
6. - Carraway, R. & Leeman, S.E. The amino acid sequence of a hypothalamic peptide, neurotensin. J Biol Chem 250, 1907-11 (1975).
Previous research has allied the DASH diet and lowfat or fat free milk to blood pressure benefits - one proof why the U.S. Dietary Guidelines for Americans recommend drinking three specs of lowfat or fat free milk each day. Milk provide nine needed nutrients, plus calcium, vitamin A, vitamin D, protein and potassium.
8. - Jegou, S., Mounien, L., Boutelet, I. & Vaudry, H. The YY3-36 peptide, a clean therapeutic weapon against obesity?. Med Sci (Paris) 19, 537-9 (2003).
9. - Soucy, J. & Leblanc, J. Protein meals and postprandial thermogenesis. Physiol Behav 65, 705-9 (1999).
10. - Johnston, C.S., Day, C.S. & Swan, P.D. Postprandial thermogenesis is increased 100% on a high-protein, diet diet versus a high-carbohydrate, low-fat diet in healthy, embryonic women. J Am Coll Nutr 21, 55-61 (2002).
11. - MacDougald, O.A., Hwang, C.S., Fan, H. & Lane, M.D. Regulated expression of the obese gene article of exchange (leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 92, 9034-7 (1995).
12. - Mizuno, T.M., Makimura, H. & Mobbs, C.V. The physiological flood of the agouti-related peptide gene: the control of weight and metabolic rate. Ann Med 35, 425-33 (2003).
acyclovir zovirax for herpes treatment on buyzoviraxonline.com store!
Also read about stomach acidity !